For the second time in less than a year, GlaxoSmithKline (GSK) is reworking promotional practices in order to boost prescriptions, and its latest move will provide greater incentives for its sales reps.

The change comes as Glaxo attempts to compete in the burgeoning oncology market, a step underscored with its recent $5 billion acquisition of Tesaro, which sells a treatment for ovarian cancer. The deal helped return the drug maker to the commercial cancer business, which demands that promotional efforts match what rivals are doing.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy